The BATTLE Trial: Personalizing Therapy for Lung Cancer
University of Maryland, Baltimore · The University of Texas MD Anderson Cancer Center · +1 more institution
Abstract
Abstract The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated, biomarker-based, adaptively randomized study in 255 pretreated lung cancer patients. Following an initial equal randomization period, chemorefractory non–small cell lung cancer (NSCLC) patients were adaptively randomized to erlotinib, vandetanib, erlotinib plus bexarotene, or sorafenib, based on relevant molecular biomarkers analyzed in fresh core needle biopsy specimens. Overall results include a 46% 8-week disease control rate (primary end point), confirm prespecified hypotheses, and show an impressive benefit from sorafenib among mutant-KRAS…
Citation impact
- FWCI
- 70.75
- Percentile
- 100%
- References
- 30
Authors
24- ESEdward S. KimCorresponding
University of Maryland, Baltimore, The University of Texas MD Anderson Cancer Center
- RSRoy S. Herbst
University of Maryland, Baltimore, The University of Texas MD Anderson Cancer Center
- IIIgnacio I. Wistuba
University of Maryland, Baltimore, The University of Texas MD Anderson Cancer Center
- JJJ. Jack Lee
University of Maryland, Baltimore, The University of Texas MD Anderson Cancer Center
- GRGeorge R. Blumenschein
University of Maryland, Baltimore, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute
Topics & keywords
- Lung cancer
- Erlotinib
- Medicine
- Sorafenib
- Oncology
- Vandetanib
- Internal medicine
- Randomized controlled trial
- Good health and well-being